[
    [
        "trial, patients who had been taking the drug for 18 months were given it for another two years.",
        "original trial, 264 of the patients with mild Alzheimer's were given solanezumab for another two years.",
        "original trial, the patients who had been on the drug for the longest had the most benefit.",
        "trial, the patients who had taken solanezumab the longest had the most benefit.",
        "trial, the patients who had been taking solanezumab for the longest had the most benefit.",
        "trial, the patients who had been on the drug the longest had the biggest benefit.",
        "trial, 268 of the patients with mild Alzheimer's took the drug for another 18 months.",
        "trial, patients were given solanezumab for an additional 18 months.",
        "trial, 173 patients were given the drug for an extra 18 months.",
        "original trial, 294 patients were given solanezumab for 30 months, 289 for 24 months and 293 for 18 months."
    ],
    [
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the trial, patients who had been taking the drug for 18 months were given it for another two years.\nThose who had been on the drug for the longest period had the most benefit.\nThey had a 32% slower rate of cognitive decline than those who had not taken the drug.\nThe",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the original trial, 264 of the patients with mild Alzheimer's were given solanezumab for another two years.\nThe results of the extension study suggest the drug is working better the longer it is taken.\nThe patients who had taken the drug for the longest period of time had a",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the original trial, the patients who had been on the drug for the longest had the most benefit.\nThe data suggests taking the drug for two years slowed the progression of the disease by about 42%, and those who took the drug for three years had a 54% reduction in the rate of progression",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the trial, the patients who had taken solanezumab the longest had the most benefit.\nThe patients who had been on the drug for 24 months had a 45% reduction in the rate of decline.\nDr Siemers said: \"The patients who had been on the drug for the",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the trial, the patients who had been taking solanezumab for the longest had the most benefit.\nThe average cognitive decline over the 18 months of the extension was 1.4 points on a scale of 70 for those taking the drug for the longest, compared with 1.9 points",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the trial, the patients who had been on the drug the longest had the biggest benefit.\nThe trial is now closed and the patients will be followed up for a year to see how they fare.\nThe results of the new trial, which has 2,100 patients, are due in 201",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the trial, 268 of the patients with mild Alzheimer's took the drug for another 18 months.\nTheir cognitive scores were compared with the 268 patients who had not taken the drug in the original trial.\nThe results suggest that the rate of decline was slower in the",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the trial, patients were given solanezumab for an additional 18 months.\nThe results suggest the longer patients took the drug, the greater the benefit.\nThe patients who had been taking the drug the longest had a 30% reduction in the rate of decline.\nThe patients who had been",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the trial, 173 patients were given the drug for an extra 18 months.\nTheir rate of cognitive decline slowed by 37%, which is very similar to the original analysis.\nIn addition, 156 patients were given a placebo for an extra 18 months.\n",
        "Write a short summary for the following passage:\nData from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.\nThe results, presented to a US conference, are being met with cautious optimism.\nA new trial is due to report next year and should provide definitive evidence.\nThe death of brain cells in Alzheimer's is currently unstoppable. Solanezumab may be able to keep them alive.\nCurrent medication, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function.\nBut solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer's.\nIt is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.\nSolanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.\nBut when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.\nIt appeared to slow progression by around 34% during the study.\nSo the company asked just over 1,000 of the patients in the original trial with mild Alzheimer's to take the drug for another two years.\nAnd positive results from this extension of the original trial have now been presented at the Alzheimer's Association International Conference.\nThey show those taking the drugs the longest had the most benefit.\nDr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: \"It's another piece of evidence that solanezumab does have an effect on the underlying disease pathology.\n\"We think there is a chance that solanezumab will be the first disease-modifying medication to be available.\"\nThe company also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.\nAnalysis\nToday is not the day to jump up and down proclaiming a breakthrough in slowing the pace of Alzheimer's.\nThe limited data which has been released is the scientific equivalent of a poll before a general election or a trailer ahead of a movie.\nIt provides captivating clues, hints and teases, but nothing definitive.\nAt the moment there is no medication that can slow down dementia. If such a drug was developed it could transform how the disease is managed.\nPeople would still get worse, but they would spend more time in the milder phase of the degenerative disease rather than needing constant care.\nIn a field that has been plagued by repeated disappointment, even a hint of such a drug is an exciting moment.\nNext year, when further trial results are due, we will know for certain whether solanezumab is the breakthrough everyone hopes it could be.\nDr Eric Karran, the director of research at Alzheimer's Research UK, told the BBC News website: \"If this gets replicated, then I think this is a real breakthrough in Alzheimer's research.\n\"Then, for the first time, the medical community can say we can slow Alzheimer's, which is an incredible step forward.\n\"These data need replicating, this is not proof, but what you can say is it is entirely consistent with a disease-modifying effect.\n\"We've never ever had evidence that we can affect the disease process.\"\nClare Walton, the research manager at the Alzheimer's Society, told the BBC: \"The data hints that the antibodies are having an effect, it is promising and it's better than no effect, but it's inconclusive.\n\"After a decade of no treatments and many drug failures, it's exciting to get promising news, but it doesn't really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.\"\nIn the first stage of the original trial, which ended in failure, half of the patients with Alzheimer's were given solanezumab and half were not.\nA reanalysis of the cognition scores of the patients with mild Alzheimer's suggested taking the drug had cut the rate of the disease's progression by about 34%.\nThe implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.\nIn the extension of the original trial, 294 patients were given solanezumab for 30 months, 289 for 24 months and 293 for 18 months.\nThe results showed the longer the patients took the drug, the greater the effect on their cognition scores.\n"
    ],
    [
        0.0,
        0.0,
        0.0,
        0.0,
        0.0,
        0.0,
        0.0,
        0.0,
        0.0,
        0.0
    ],
    [
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.5361328721046448,
            0.15024584531784058,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.7828087210655212,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.543960452079773,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.40716782212257385,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.10903888195753098,
            0.08994258940219879,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            1.0,
            0.6361542344093323,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.9366660714149475
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.03130593150854111,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            1.0
        ]
    ],
    [
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -0.62337327003479,
            -1.8954823017120361,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -0.24486690759658813,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -0.6088787913322449,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -0.8985298871994019,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -2.216050624847412,
            -2.408583641052246,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            0.0,
            -0.4523142874240875,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -0.06542844325304031
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -3.4639477729797363,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            0.0
        ]
    ],
    1196
]